The institutional investor owned 70,500 shares of the company’s stock after selling 45,184 shares during the quarter. J. Safra Sarasin Holding AG owned 0.06% of Apellis Pharmaceuticals worth $1,595,000 at the end of the most recent reporting period. Finally, Camber Capital Management LP acquired a new position in shares of Apellis Pharmaceuticals during the 2nd quarter worth approximately $14,714,000. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $16.10 and a fifty-two week high of $30.60. See AlsoReceive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.